Treatments in Oncology
RSSArticles
-
Momelotinib Tablets (Ojjaara)
Momelotinib can be prescribed to treat intermediate- or high-risk myelofibrosis.
-
Lack of Transparency on Informed Consent Documents Complicates Oncology Trials
Researchers should describe the potential benefits and risks of participating in the trial compared with potential benefits and risks of receiving standard treatment outside the trial. Also, strive to write consent forms that highlight the key issues involved in the decision to join a trial.
-
Advance Care Planning Can Lower Odds of Aggressive End-of-Life Treatment
Advance care planning was associated with significantly lower odds of indicators of aggressive end-of-life care (i.e., hospital death, hospital admissions, intensive care, delayed hospice referrals, and chemotherapy). Cancer patients who engaged in advance care planning were 50% more likely to complete Do Not Resuscitate orders compared to cancer patients without an advance directive.
-
Mediterranean Diet Pairs Well with Immune Checkpoint Blockade
The popular healthy diet boosted response to unique cancer therapy among patients with advanced melanoma.
-
MicroRNA Could Help Oncologists Craft Better Treatment Plans for Breast Cancer Patients
Researchers have been searching for biomarkers that are good predictors of cancer recurrence and mortality.
-
Parents, IRBs Hold Different Views on Phase I Pediatric Oncology Trials
IRB members are more likely than the public to think the risks outweigh the potential medical benefits. Parents think about the possibility of caring for a child with severe cancer and no treatment alternatives. IRBs ensure trials are ethical and that pediatric subjects are not exposed to excessive risk.
-
Cancer Death Rate for Black Americans Declines, Remains Higher Than That of Other Groups
Rapid declines in deaths from lung and stomach cancers parallels rise in mortality from uterine and liver cancers.
-
Unique Challenges for IRBs Evaluating Radiation Oncology Study Protocols
There may be few if any radiation oncology investigators at some institutions, and radiation therapy involves rapidly advancing technology. In light of this, IRBs might lack the necessary expertise to review these studies.
-
Exploring the Cardio-Oncology Frontier
Investigators found a new cancer diagnosis was independently associated with a higher risk for cardiovascular death and nonfatal morbidity.
-
Preventing Age Disparities in Cancer Trials
A leading researcher explains why patients should have equity regarding their ability to access clinical trials, to the greatest extent reasonably possible, in this Q&A.